CL2021000081A1 - Derivados de tiadiazina - Google Patents
Derivados de tiadiazinaInfo
- Publication number
- CL2021000081A1 CL2021000081A1 CL2021000081A CL2021000081A CL2021000081A1 CL 2021000081 A1 CL2021000081 A1 CL 2021000081A1 CL 2021000081 A CL2021000081 A CL 2021000081A CL 2021000081 A CL2021000081 A CL 2021000081A CL 2021000081 A1 CL2021000081 A1 CL 2021000081A1
- Authority
- CL
- Chile
- Prior art keywords
- thiadiazine derivatives
- thiadiazine
- derivatives
- racemates
- diastereomers
- Prior art date
Links
- 150000008334 thiadiazines Chemical class 0.000 title abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 abstract 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Derivados de tiadiazina o sales, metabolitos biológicamente activos, profármacos, racematos, enantiómeros, diastereómeros, solvatos o hidratos farmacéuticamente aceptables de éstos, así como composiciones farmacéuticas que los contienen y su uso como moduladores de la actividad del receptor nicotínico de acetilcolina α7 en un sujeto mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1800249A HU231414B1 (hu) | 2018-07-13 | 2018-07-13 | Tiadiazin származékok |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000081A1 true CL2021000081A1 (es) | 2021-10-29 |
Family
ID=89992726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000081A CL2021000081A1 (es) | 2018-07-13 | 2021-01-12 | Derivados de tiadiazina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20210267993A1 (es) |
| EP (1) | EP3820865A1 (es) |
| JP (2) | JP7440486B2 (es) |
| KR (1) | KR20210033003A (es) |
| CN (1) | CN112424198A (es) |
| AR (1) | AR115783A1 (es) |
| AU (1) | AU2019300515A1 (es) |
| BR (1) | BR112020027016A2 (es) |
| CA (1) | CA3104264A1 (es) |
| CL (1) | CL2021000081A1 (es) |
| CO (1) | CO2021001224A2 (es) |
| CU (1) | CU24622B1 (es) |
| EA (1) | EA202190246A1 (es) |
| GE (1) | GEP20237459B (es) |
| HU (1) | HU231414B1 (es) |
| IL (1) | IL279939A (es) |
| MX (1) | MX2021000461A (es) |
| PE (1) | PE20210465A1 (es) |
| PH (1) | PH12021550007A1 (es) |
| SG (1) | SG11202012769QA (es) |
| TW (1) | TWI827628B (es) |
| WO (1) | WO2020012423A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230131668A1 (en) * | 2020-02-14 | 2023-04-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Heat shock protein modulators and anti-huntington disease therapeutic agents |
| TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5341516B2 (ja) | 2005-09-13 | 2013-11-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ２−アニリン−４−アリール置換チアゾール誘導体 |
| KR101186704B1 (ko) | 2007-10-04 | 2012-09-27 | 에프. 호프만-라 로슈 아게 | 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도 |
| ES2460897T3 (es) | 2007-10-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Derivados de ciclopropil aril amida y usos de los mismos |
| US8536221B2 (en) | 2008-02-07 | 2013-09-17 | Abbvie Inc. | Amide derivatives as positive allosteric modulators and methods of use thereof |
| CN102066343B (zh) | 2008-03-19 | 2013-12-04 | 詹森药业有限公司 | 作为烟碱乙酰胆碱受体调节剂的三取代1，2，4-三唑类 |
| ES2392795T3 (es) | 2008-04-17 | 2012-12-13 | Proximagen Limited | Indoles como moduladores del receptor nicotínico de acetilcolina de subtipo alfa-7 |
| WO2009135944A1 (en) | 2008-05-09 | 2009-11-12 | Janssen Pharmaceutica Nv | Trisubstituted pyrazoles as acetylcholine receptor modulators |
| CN102666540A (zh) * | 2009-10-13 | 2012-09-12 | Msd欧斯股份有限公司 | 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 |
| WO2012104782A1 (en) * | 2011-02-03 | 2012-08-09 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
| JP2016512225A (ja) * | 2013-03-13 | 2016-04-25 | ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ | アルファー７ｎａｃｈｒモジュレータとしてのピロール誘導体 |
| GEP20207149B (en) * | 2016-03-22 | 2020-09-10 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
| EP3534888B1 (en) | 2016-11-01 | 2022-04-06 | Merck Sharp & Dohme Corp. | Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| ES2898217T3 (es) * | 2017-03-02 | 2022-03-04 | Assembly Biosciences Inc | Compuestos de sulfamida cíclica y métodos de uso de los mismos |
-
2018
- 2018-07-13 HU HUP1800249A patent/HU231414B1/hu unknown
-
2019
- 2019-06-27 TW TW108122604A patent/TWI827628B/zh active
- 2019-07-12 PE PE2021000052A patent/PE20210465A1/es unknown
- 2019-07-12 AR ARP190101992A patent/AR115783A1/es unknown
- 2019-07-12 EP EP19744869.9A patent/EP3820865A1/en active Pending
- 2019-07-12 BR BR112020027016-4A patent/BR112020027016A2/pt unknown
- 2019-07-12 EA EA202190246A patent/EA202190246A1/ru unknown
- 2019-07-12 AU AU2019300515A patent/AU2019300515A1/en active Pending
- 2019-07-12 CU CU2020000109A patent/CU24622B1/es unknown
- 2019-07-12 SG SG11202012769QA patent/SG11202012769QA/en unknown
- 2019-07-12 WO PCT/IB2019/055949 patent/WO2020012423A1/en unknown
- 2019-07-12 GE GEAP201915558A patent/GEP20237459B/en unknown
- 2019-07-12 US US17/259,975 patent/US20210267993A1/en active Pending
- 2019-07-12 CA CA3104264A patent/CA3104264A1/en active Pending
- 2019-07-12 CN CN201980046660.4A patent/CN112424198A/zh active Pending
- 2019-07-12 MX MX2021000461A patent/MX2021000461A/es unknown
- 2019-07-12 JP JP2021500540A patent/JP7440486B2/ja active Active
- 2019-07-12 KR KR1020217004286A patent/KR20210033003A/ko unknown
-
2021
- 2021-01-04 PH PH12021550007A patent/PH12021550007A1/en unknown
- 2021-01-04 IL IL279939A patent/IL279939A/en unknown
- 2021-01-12 CL CL2021000081A patent/CL2021000081A1/es unknown
- 2021-02-03 CO CONC2021/0001224A patent/CO2021001224A2/es unknown
-
2024
- 2024-02-14 JP JP2024020524A patent/JP2024056879A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210033003A (ko) | 2021-03-25 |
| JP2024056879A (ja) | 2024-04-23 |
| IL279939A (en) | 2021-03-01 |
| PH12021550007A1 (en) | 2021-09-20 |
| BR112020027016A2 (pt) | 2021-04-06 |
| PE20210465A1 (es) | 2021-03-08 |
| MX2021000461A (es) | 2021-06-23 |
| TWI827628B (zh) | 2024-01-01 |
| EA202190246A1 (ru) | 2021-04-20 |
| CU20200109A7 (es) | 2021-08-06 |
| AR115783A1 (es) | 2021-02-24 |
| EP3820865A1 (en) | 2021-05-19 |
| SG11202012769QA (en) | 2021-02-25 |
| HUP1800249A2 (en) | 2020-01-28 |
| CU24622B1 (es) | 2022-09-08 |
| CO2021001224A2 (es) | 2021-02-17 |
| JP2021529813A (ja) | 2021-11-04 |
| CN112424198A (zh) | 2021-02-26 |
| WO2020012423A1 (en) | 2020-01-16 |
| JP7440486B2 (ja) | 2024-02-28 |
| US20210267993A1 (en) | 2021-09-02 |
| AU2019300515A1 (en) | 2021-02-11 |
| GEP20237459B (en) | 2023-01-25 |
| HU231414B1 (hu) | 2023-08-28 |
| CA3104264A1 (en) | 2020-01-16 |
| TW202019431A (zh) | 2020-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001224A2 (es) | Derivados de tiadiazina | |
| ECSP20003147A (es) | Carboxamidas como moduladores de los canales de sodio | |
| CO2021001216A2 (es) | Derivados de espirocromano | |
| DOP2023000016A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
| UY38979A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| MX369347B (es) | Derivados de pirrolidinilsulfona y su uso como moduladores del receptor huerfano relacionado con retinoide gamma (ror gamma). | |
| UY36673A (es) | Sulfonas tricíclicas como moduladores de ror y composiciones farmacéuticas que las contienen | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| CO2020013550A2 (es) | Inhibidores de magl | |
| PE20151427A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| CL2019000249A1 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
| GT201700231A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| AR122973A1 (es) | Compuestos de piperidina sustituida y su uso | |
| CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| CO2019004164A2 (es) | Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| MX2019005384A (es) | Sulfonas triciclicas como moduladores del receptor huerfano relacionado con retinoide (ror) gamma. | |
| CL2021002144A1 (es) | Compuesto heterociclo pentacíclico. | |
| CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
| CL2023001608A1 (es) | Moduladores de progranulina y métodos de uso de los mismos | |
| AR102887A1 (es) | Una triazolopiridazina como modulador de quinasa |